In comparison to anti-TNFRSF14 mono-treatment, the combination of TNFRSF14 and PD-L1 blockade remarkably extend the survival of tumor-bearing mice (Fig. 6H and Figure S7B). This evidence concerns the gene CD274 and neoplasm.